×
About 10,318 results

ALLMedicine™ Ankylosing Spondylitis Center

Research & Reviews  2,732 results

TNF-α inhibitor-induced paradoxical psoriasis and erythema nodosum in a patient with an...
https://doi.org/10.1684/ejd.2021.4058
European Journal of Dermatology : EJD; Watabe D, Amano H

Jul 27th, 2021 - TNF-α inhibitor-induced paradoxical psoriasis and erythema nodosum in a patient with ankylosing spondylitis.|2021|Watabe D,Amano H,|

Gastroenterological safety of IL-17 inhibitors: a systematic literature review.
https://doi.org/10.1080/14740338.2021.1960981
Expert Opinion on Drug Safety; Caron B, Jouzeau JY et. al.

Jul 27th, 2021 - Interleukin 17 is a proinflammatory cytokine considered to play a significant role in the immunopathogenesis of many chronic immune-mediated disorders. Interleukin 17 inhibitors provide an excellent treatment option for patients with psoriasis, ps...

The combined prevalence of classified rare rheumatic diseases is almost double that of ...
https://doi.org/10.1186/s13023-021-01945-8 10.1007/s00103-013-1688-3 10.1007/s00296-011-1849-3 10.1080/03009740510026616 10.1136/annrheumdis-2015-eular.1929 10.3109/14397595.2014.974881 10.1002/ajh.21888 10.1038/ng720 10.1186/1546-0096-12-33 10.1136/annrheumdis-2013-204991 10.1038/ng756 10.1038/ng0997-25 10.1016/S0092-8674(00)80539-5 10.1111/pai.12490 10.2174/1874312901307010022 10.1111/cei.12463 10.1111/jpc.12172 10.1097/BOR.0b013e32835d8e2a 10.1111/j.1365-2133.1995.tb08638.x 10.1016/j.ajhg.2011.11.019 10.1111/j.1399-0004.2005.00533.x 10.1136/jmg.2005.033522 10.3109/07853890.2014.971052 10.2174/138920210793175921 10.1016/j.autrev.2014.08.017 10.1136/annrheumdis-2016-209909 10.1016/S1474-4422(07)70171-0 10.7326/0003-4819-122-11-199506010-00008 10.1056/NEJMoa0909905 10.1016/j.jpeds.2007.03.015 10.1002/art.39995 10.1136/annrheumdis-2014-206580 10.1136/annrheumdis-2011-201268 10.1002/art.24458 10.1016/j.autrev.2013.11.005 10.1002/art.1780390814 10.1097/BOR.0b013e32834ff2e8 10.1097/BOR.0000000000000480 10.1016/j.autrev.2012.09.004 10.1016/j.jaut.2015.06.005 10.2188/jea.JE20140089 10.1186/1750-1172-1-14 10.6061/clinics/2016(07)08 10.1093/rheumatology/kel388 10.1016/S0167-5273(98)00175-2 10.1056/NEJM200009213431207 10.3109/14397595.2013.857582 10.1002/art.20077 10.1093/rheumatology/kem107 10.1002/art.37721 10.1097/BOR.0000000000000015 10.1016/j.autrev.2014.12.004 10.1002/art.1780330806 10.1111/bjd.12642 10.1186/1750-1172-8-10 10.1186/1750-1172-8-185 10.1186/1750-1172-8-52 10.1186/1750-1172-6-15 10.1002/art.38956 10.1002/art.38010 10.2169/internalmedicine.50.4515 10.2188/jea.JE20110131 10.1136/archdischild-2014-307536 10.1097/BOR.0000000000000010 10.1016/j.mayocp.2014.04.015 10.1111/jdv.13952 10.1016/j.jaut.2014.01.023 10.1016/j.autrev.2015.05.005 10.1002/art.24149 10.1186/1750-1172-7-20 10.1136/ard.2007.080432 10.1111/j.1529-8019.2010.01332.x 10.1016/j.det.2008.05.007 10.1136/annrheumdis-2016-210802 10.1016/j.autrev.2016.02.015 10.1016/j.jaut.2014.01.007 10.1002/art.39068 10.1097/00005792-198801000-00002 10.1016/j.semarthrit.2005.08.007 10.1016/j.ijcard.2017.02.086 10.1093/rheumatology/kep153 10.1002/acr.22931 10.1016/j.ajhg.2013.05.026 10.1016/j.jaut.2014.01.028 10.1097/00005792-200205000-00003 10.1002/ajmg.a.30906 10.1172/JCI32001 10.1002/ajmg.c.31333 10.1086/343053 10.1086/302186 10.1016/j.jbspin.2004.01.011 10.1086/343054 10.2147/OARRR.S39039 10.1093/rheumatology/keu230 10.1097/00005792-198005000-00004 10.1016/j.autrev.2010.07.001 10.1016/S1470-2045(15)00132-1 10.1002/art.33432 10.1002/art.10497 10.1016/j.berh.2004.05.002 10.1016/j.semarthrit.2011.08.008 10.1007/s11926-015-0525-0 10.1080/14397595.2016.1192744 10.1007/s12016-013-8362-2 10.1111/j.1471-0528.2004.00482.x 10.1016/S0049-0172(99)80027-4 10.1016/j.semarthrit.2013.10.010 10.1016/j.semarthrit.2012.05.006 10.1016/j.jinf.2016.04.030 10.1007/s11832-014-0627-7 10.1016/S0140-6736(11)60244-4 10.1016/j.berh.2009.08.003 10.1038/ncprheum0084 10.1136/annrheumdis-2016-210324 10.1093/rheumatology/ken409 10.1002/art.10882 10.1136/ard.2010.134254 10.1136/annrheumdis-2014-205265 10.1128/JCM.01517-12 10.1111/1469-0691.12724 10.1086/528693 10.1053/j.gastro.2009.10.041 10.1016/j.jinf.2012.12.004 10.7326/0003-4819-153-11-201012070-00004 10.1093/jac/dkt310 10.1055/s-0041-100846 10.1016/j.joca.2017.07.005 10.5435/00124635-201105000-00008 10.1177/0363546506290127 10.1002/art.22966 10.1002/art.24533 10.1093/rheumatology/keu437 10.1111/j.1651-2227.2004.tb00670.x 10.1002/art.39519 10.1136/ard.2010.138420 10.1007/s00281-015-0491-7 10.1016/j.jbspin.2010.09.021 10.1136/annrheumdis-2012-202708 10.5152/eurjrheum.2014.006 10.1093/rheumatology/ken509 10.1002/art.1780401023 10.1186/1750-1172-1-13 10.1007/s00296-011-2180-8 10.1002/acr.23120 10.1097/MD.0b013e318190cfb7 10.1073/pnas.1106015108 10.1111/ijd.12695 10.2332/allergolint.11-RAI-0416 10.1136/ard.2009.126185 10.1093/hmg/11.8.961 10.1016/S0025-6196(11)63565-9 10.1086/302866 10.1111/apa.12069 10.1016/S0022-3476(99)70321-5 10.1016/S0022-3476(87)80285-8 10.1111/all.12129 10.1016/j.jaci.2016.07.041 10.1016/j.autrev.2011.01.003 10.1111/all.13035 10.1093/rheumatology/kep418 10.1002/art.38769 10.1136/annrheumdis-2015-208982 10.1002/pbc.21039 10.1002/art.38802 10.1016/j.autrev.2016.09.016 10.1136/jmg.2005.030759 10.1136/annrheumdis-2012-201818 10.1136/annrheumdis-2013-204184 10.1093/rheumatology/kep140 10.1136/annrheumdis-2012-201952 10.1097/RHU.0000000000000427 10.1007/s11926-008-0053-2 10.1016/j.autrev.2014.03.004 10.1007/s12016-016-8528-9 10.1097/01.LAB.0000098428.51765.83 10.3109/14397595.2013.844308 10.1136/annrheumdis-2013-205127 10.1097/RHU.0b013e3182a21ba8 10.1111/ene.12627 10.1002/mus.24562 10.1016/j.nmd.2016.08.014 10.1097/PAS.0b013e31819e63fe 10.1038/gim.2015.9 10.1186/s12864-017-4188-2 10.1007/s10545-014-9743-2 10.1016/j.nmd.2011.10.022 10.1038/79128 10.1002/ajmg.a.36692 10.1016/j.bone.2012.07.002 10.1001/jama.281.3.249 10.1186/s13023-015-0253-6 10.1186/1546-0096-5-15 10.1016/j.ymgme.2013.04.019 10.1186/1750-1172-9-45 10.1186/1750-1172-7-77 10.1080/10245332.2016.1240391 10.1111/apa.14760 10.1111/j.1469-1809.2011.00642.x 10.1007/s10545-007-0529-7 10.1002/ajmg.a.36833 10.1007/s11914-017-0375-y 10.1016/j.pmrj.2016.07.530 10.1007/s003300000562 10.1038/jid.2012.146 10.3346/jkms.2016.31.5.735 10.1038/ng.153 10.1007/s13353-014-0262-5 10.1111/j.1651-2227.2008.00965.x 10.1007/s00431-013-2252-8 10.1172/JCI22760 10.1186/1750-1172-2-32 10.1111/j.1399-0004.2012.01858.x 10.1002/ajmg.c.31552 10.1016/j.clinimag.2015.07.008 10.1148/radiographics.21.3.g01ma17737 10.3109/s10165-011-0508-6 10.1136/annrheumdis-2018-214603 10.1002/art.41120 10.1136/jmg.2009.072785 10.1016/S0140-6736(05)67789-6 10.1016/j.autrev.2014.01.019 10.1007/s11926-017-0700-6 10.1136/ard.2010.143792 10.1016/j.jaut.2014.01.008 10.3109/03009749709065713 10.1097/00005792-200203000-00004 10.1136/annrheumdis-2013-204424 10.1002/art.11073 10.1111/cge.12832 10.1002/ajmg.a.36836 10.1016/j.ajhg.2012.05.006 10.1002/ajmg.a.36552 10.1111/j.1365-4632.2006.02940.x 10.1016/j.jvsv.2016.10.084 10.1002/ajmg.a.37868 10.1056/NEJMoa1104017 10.1111/cge.12266 10.1002/ajmg.a.30327 10.1016/j.critrevonc.2015.02.004 10.1182/blood-2014-03-561381 10.1136/annrheumdis-2012-202542 10.1186/1750-1172-8-137 10.1086/378418 10.1542/peds.2006-0824 10.1016/j.jaad.2007.06.008 10.1007/s12016-012-8351-x 10.1186/1750-1172-2-34 10.1016/S0190-9622(96)90080-8 10.1016/S0190-9622(94)70215-2 10.2147/CLEP.S91439 10.1002/art.39790 10.1016/j.semarthrit.2011.12.007 10.7326/0003-4819-104-1-74 10.1097/00005792-197605000-00001 10.1288/00005537-197906000-00009 10.1016/j.autrev.2017.10.005 10.4065/81.4.483 10.1007/s12016-013-8406-7 10.1016/S0190-9622(98)70402-5 10.1111/bjh.12916 10.1182/blood-2009-02-205237 10.1002/ajh.24553 10.1002/ajh.24382 10.1182/blood-2016-09-731893 10.1136/postgradmedj-2014-132584 10.1007/s12016-015-8475-x
Orphanet Journal of Rare Diseases; Leyens J, Bender TTA et. al.

Jul 24th, 2021 - Rare diseases (RDs) affect less than 5/10,000 people in Europe and fewer than 200,000 individuals in the United States. In rheumatology, RDs are heterogeneous and lack systemic classification. Clinical courses involve a variety of diverse symptoms...

see more →

Guidelines  11 results

2019 Update of the American College of Rheumatology/Spondylitis Association of America/...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764882
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.

Aug 23rd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...

Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients ...
https://www.ncbi.nlm.nih.gov/pubmed/30717501
Pain Physician; Kaye AD, Manchikanti L et. al.

Feb 6th, 2019 - Interventional pain management involves diagnosis and treatment of chronic pain. This specialty utilizes minimally invasive procedures to target therapeutics to the central nervous system and the spinal column. A subset of patients encountered in ...

The effectiveness, safety, and economic evaluation of Korean medicine for unexplained i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779787
Medicine

Mar 6th, 2018 - Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the ...

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
https://doi.org/10.1136/annrheumdis-2016-210770
Annals of the Rheumatic Diseases; van der Heijde D, Ramiro S et. al.

Jan 15th, 2017 - To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with...

EULAR recommendations for cardiovascular disease risk management in patients with rheum...
https://doi.org/10.1136/annrheumdis-2016-209775
Annals of the Rheumatic Diseases; Agca R, Heslinga SC et. al.

Oct 5th, 2016 - Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommend...

see more →

Drugs  762 results see all →

Clinicaltrials.gov  133 results

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease
https://clinicaltrials.gov/ct2/show/NCT03201445

Apr 16th, 2020 - The primary objective of this study is to evaluate the testicular safety of filgotinib in adult males with moderately to severely active inflammatory bowel disease. Results of this study may be pooled with the results of a separate study being con...

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis
https://clinicaltrials.gov/ct2/show/NCT03350815

Apr 14th, 2020 - Study estimating the clinical difference between 300 mg and 150 mg of secukinumab following dose escalation to 300 mg in patients with ankylosing spondylitis

Clinical Pilates and Aerobic Exercise in Patients With Ankylosing Spondylitis
https://clinicaltrials.gov/ct2/show/NCT03211559

Apr 13th, 2020 - According to the power analyzes 32 patients, who were diagnosed as Ankylosing spondylitis, will be taken to the study. In the first session their spinal mobility, flexibility, dynamic and static balance, back and lower limb muscle strength, pulmon...

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis
https://clinicaltrials.gov/ct2/show/NCT03215277

Apr 9th, 2020 - The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared to certolizumab pegol in the treatment of subjects with active ankylosing spondylitis (AS).

Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
https://clinicaltrials.gov/ct2/show/NCT00056719

Apr 6th, 2020 - The susceptibility to ankylosing spondylitis (AS) is largely genetically determined. Recent studies suggest that the severity of AS is also influenced by genetic factors. The goal of this study is to identify genes that influence the severity of A...

see more →

News  479 results

Fast Five Quiz: Ankylosing Spondylitis Management
https://reference.medscape.com/viewarticle/932595

May 27th, 2021 - Ankylosing spondylitis (AS) is a recurrent, progressive autoimmune disease that is associated with a high rate of disability. AS is characterized by inflammatory back pain, radiographic sacroiliitis, excess spinal bone formation, and a high preval...

Fast Five Quiz: Ankylosing Spondylitis Management
https://www.medscape.com/viewarticle/932595

May 27th, 2021 - Ankylosing spondylitis (AS) is a recurrent, progressive autoimmune disease that is associated with a high rate of disability. AS is characterized by inflammatory back pain, radiographic sacroiliitis, excess spinal bone formation, and a high preval...

Brodalumab Shows Promise in Axial Spondyloarthritis
https://www.medscape.com/viewarticle/950264

May 3rd, 2021 - NEW YORK (Reuters Health) - Brodalumab may be a potential therapeutic option for patients with axial spondyloarthritis (axSpA), according to interim results of a phase-3 study. Brodalumab, which selectively inhibits interleukin-17 receptor A (IL-1...

Major Advance in the Treatment of Axial Spondyloarthritis Coming
https://www.medscape.com/viewarticle/946520

Feb 26th, 2021 - Rheumatologists can look forward to the likely regulatory approval of the oral Janus kinase inhibitors tofacitinib and upadacitinib for the treatment of axial spondyloarthritis in the first half of 2021, speakers predicted at the 2021 Rheumatology...

Etanercept May Not Help Some With Suspected Nonradiographic Axial Spondyloarthritis
https://www.medscape.com/viewarticle/942849

Dec 17th, 2020 - Treatment with etanercept does not appear to achieve significant clinical improvement in patients suspected of having nonradiographic axial spondyloarthritis (nr-axSpA) but without positive MRI signs of sacroiliitis and/or elevated C-reactive prot...

see more →

Patient Education  10 results see all →